Literature DB >> 17628494

Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies.

Shuhua Bai1, Tianzhi Yang, Thomas J Abbruscato, Fakhrul Ahsan.   

Abstract

This study tests the hypothesis that human nasal RPMI 2650 cells grown at an air-liquid interface is a feasible model for drug transport studies via the nasal route. RPMI 2650 cells were cultured in Eagle's minimal essential medium (MEM) at both air-liquid and liquid-liquid interfaces. For each culture regimen, monolayer integrity was tested by measuring the transepithelial resistance (TEER) as well as the transport of paracellular and transcellular markers across the monolayer. The expression of tight junction proteins-differentiation markers-in cells of the different monolayers was studied by western blot analysis and confocal microscopy. The highest TEER values (192 +/- 3 Omega . cm2) were observed for RPMI 2650 cells seeded onto collagen-coated permeable polytetrafluoroethylene inserts and grown at an air-liquid interface for 10 days; a seeding density of 4 x 10(5)/cm2 generated and maintained a cell monolayer with suitable barrier properties at days 9-12. Microscopic examination showed that RPMI 2650 cells grown on filter inserts formed a fully confluent monolayer. The apparent permeability coefficients of the paracellular marker, [14C] mannitol, and the transcellular marker, [3H] propranolol, were 5.07 +/- 0.01 x 10(-6) cm/s and 16.1 +/- 0.1 x 10(-6) cm/s, respectively. Western blot analysis indicated the presence of four tight junction proteins: ZO-1, occludin, claudin-1 and E-cadherin; and the quantities of ZO-1, occludin, and E-cadherin were significantly higher in cells grown at an air-liquid interface than in cells grown at a liquid-liquid interface. Confocal microscopic studies showed ZO-1, F-actin, occludin and claudin-1 proteins at cell-cell contacts and revealed significant differences in the distributions and densities of ZO-1 protein in cells grown at the two types of interface. The data indicate that RPMI 2650 cells grown at an air-liquid interface form polarized monolayers with the cells interconnected by tight junction proteins. This human nasal cell line model could provide a useful tool for in vitro screening of nasal drug candidates. (Copyright) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 17628494     DOI: 10.1002/jps.21031

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  16 in total

Review 1.  Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?

Authors:  Clément Mercier; Nathalie Perek; Xavier Delavenne
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.441

2.  Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability.

Authors:  Levente Kürti; Szilvia Veszelka; Alexandra Bocsik; Béla Ozsvári; László G Puskás; Agnes Kittel; Piroska Szabó-Révész; Mária A Deli
Journal:  Cytotechnology       Date:  2012-09-02       Impact factor: 2.058

3.  The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model.

Authors:  Mateja Erdani Kreft; Urška Dragin Jerman; Eva Lasič; Tea Lanišnik Rižner; Neli Hevir-Kene; Luka Peternel; Katja Kristan
Journal:  Pharm Res       Date:  2014-08-22       Impact factor: 4.200

4.  Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer.

Authors:  Tianzhi Yang; Brittany Fogarty; Bret LaForge; Salma Aziz; Thuy Pham; Leanne Lai; Shuhua Bai
Journal:  AAPS J       Date:  2016-11-23       Impact factor: 4.009

5.  Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio.

Authors:  Tianzhi Yang; Paige Martin; Brittany Fogarty; Alison Brown; Kayla Schurman; Roger Phipps; Viravuth P Yin; Paul Lockman; Shuhua Bai
Journal:  Pharm Res       Date:  2015-01-22       Impact factor: 4.200

Review 6.  Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS.

Authors:  Anupam Sarma; Malay K Das
Journal:  Mol Biomed       Date:  2020-12-10

7.  Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity.

Authors:  Pamela T Wong; Su He Wang; Susan Ciotti; Paul E Makidon; Douglas M Smith; Yongyi Fan; Charles F Schuler; James R Baker
Journal:  Mol Pharm       Date:  2013-12-13       Impact factor: 4.939

8.  CNS Delivery and Anti-Inflammatory Effects of Intranasally Administered Cyclosporine-A in Cationic Nanoformulations.

Authors:  Sunita Yadav; Grishma Pawar; Praveen Kulkarni; Craig Ferris; Mansoor Amiji
Journal:  J Pharmacol Exp Ther       Date:  2018-12-27       Impact factor: 4.030

9.  Hypoxia increases epithelial permeability in human nasal epithelia.

Authors:  Hyun Jin Min; Tae Hoon Kim; Joo-Heon Yoon; Chang-Hoon Kim
Journal:  Yonsei Med J       Date:  2015-05       Impact factor: 2.759

10.  Evaluation of nasal epithelium sampling as a tool in the preclinical development of siRNA-based therapeutics for asthma.

Authors:  Gareth D Healey; Neil Evans; Julian M Hopkin; Gwyneth Davies; William Walker
Journal:  J Cell Mol Med       Date:  2013-02-13       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.